Sagent Pharmaceuticals Inc  

(Public, NASDAQ:SGNT)   Watch this stock  
Find more results for Ronald J Moran´┐Ż
21.69
+0.02 (0.09%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 21.65 - 21.72
52 week 10.55 - 25.89
Open 21.70
Vol / Avg. 848,178.00/1.31M
Mkt cap 345.29M
P/E     -
Div/yield     -
EPS -0.76
Shares 32.84M
Beta 1.47
Inst. own 100%
Aug 8, 2016
Q2 2016 Sagent Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 3, 2016
Q1 2016 Sagent Pharmaceuticals Inc Earnings Release
May 3, 2016
Q1 2016 Sagent Pharmaceuticals Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -7.36% -6.87%
Operating margin -10.65% -13.99%
EBITD margin - 5.35%
Return on average assets -5.75% -6.00%
Return on average equity -7.93% -8.34%
Employees 440 -
CDP Score - -

Address

1901 N Roselle Rd Ste 700
SCHAUMBURG, IL 60195-3194
United States - Map
+1-847-9081604 (Phone)
+1-847-9081601 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Sagent Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market. It operates through two segments: Sagent US, consisting of the Company's operations in the United States and the Sagent (China) Pharmaceuticals Co. Ltd. (SCP) manufacturing facility, and Omega, which is focused on the Canadian and international markets. It offers a range of products across anti-infective, oncology and critical care indications in a range of presentations, including single and multi-dose vials, pre-filled ready-to-use syringes and premix bags. Its Sagent US product portfolio includes approximately 60 marketed products that it offers in over 180 presentations, and its Omega segment offers over 50 products.

Officers and directors

Jeffrey M. Yordon Chairman of the Board, President, Chief Executive Officer
Age: 65
Bio & Compensation  - Reuters
Jonathon M. Singer Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
Ronald Edwin Pauli Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
Frank Harmon Executive Vice President - Global Operations
Age: 61
Bio & Compensation  - Reuters
Dave Hebeda Vice President - Finance
Age: 43
Bio & Compensation  - Reuters
Jeffrey Greve CPA Vice President - Controller
Age: 40
Bio & Compensation  - Reuters
Anthony Gulczynski Vice President - Corporate Development
Age: 53
Bio & Compensation  - Reuters
Ravi Malhotra Ph.D. Vice President - Project Management
Age: 68
Bio & Compensation  - Reuters
Sheila Moran Vice President - Quality
Age: 44
Bio & Compensation  - Reuters
Tom Moutvic Vice President - Regulatory Affairs
Age: 48
Bio & Compensation  - Reuters